In today’s Pharmaceutical Executive Daily, we cover AbbVie’s new API manufacturing site in Illinois, AstraZeneca’s plan to ...

Kedrion Biopharma celebrates FDA approval of Qivigy, enhancing treatment options for primary immunodeficiency while ...

The same Wall Street Journal report also states that Pfizer will announce plans to lower drug costs in response to the ...

Novo Nordisk aims to revolutionize diabetes care with Awiqli, a potential once-weekly insulin, resubmitted for FDA approval ...

Craig Thompson, CEO of Cerevance discusses the key scientific and clinical insights that lead to Cerevance's pursuit of Solengepras.

The MFN executive order may result in the US losing its place as the friendliest market for innovation.

Genmab's acquisition of Merus for $8 billion enhances its oncology portfolio, promising growth and innovative therapies like ...

GSK appoints Luke Miels as CEO designate, set to lead the company into a pivotal growth phase starting January 2026.

The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a ...

AbbVie officially began construction on its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, ...

In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s ...

The FDA has expanded Johnson & Johnson’s Tremfya (guselkumab) approval to children six years and older weighing at least 40 ...